Du är här

2014-05-20

Santhera Pharmaceuticals Holding AG: Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting

Santhera Pharmaceuticals Holding AG / Santhera's Shareholders Approve all
Board Proposals at Annual Shareholders'Meeting . Processed and transmitted by
NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
Liestal, Switzerland, May 20, 2014
- Santhera Pharmaceuticals (SIX: SANN) announced today that at its
Annual Shareholders' Meeting, a large majority of shareholders represented
approved all proposals by the Board of Directors (Board). In particular,
shareholders voted in favor of the proposed
appropriation of the results and the creation of new authorized and
conditional capitals
.Board members Martin Gertsch (Chairman) and Jürg Ambühl were both re-elected.

A total of 2,057,189 shares or 44.9 % of the share capital was represented at
the Shareholders' Meeting. Details of the agenda items are available from the
Company's website
www.santhera.comunderInvestors/Shareholders' Meeting.

Shareholders approved the 2013 Annual Report, the annual financial statements
and the consolidated financial statements as well as the proposed
appropriation of the results. The reports of the auditors were acknowledged
and the members of the Board and the management discharged. Shareholders also
approved a renewal of authorized and both an increase of existing conditional
share capital and a creation of additional conditional share capital. In
addition, several amendments to the Company's Articles of Incorporation as
required by the Ordinance Against Excessive Compensation ("Minder
Initiative") were voted on favorably.

Martin Gertsch was re-elected as member and elected as Chairman of the Board.
Shareholders also re-elected Jürg Ambühl as Board member. Both gentlemen were
elected as members of the Compensation Committee. Finally Ernst & Young,
Basel, were re-appointed as auditors and Balthasar Settelen, Basel, as
independent proxy. All elections are for a period of one year until the next
ordinary shareholders' meeting.

Martin Gertsch, Chairman of the Board, explained: "In line with the mandate
received last year, we preserved our key assets and advanced their
development. The recently communicated positive outcome of the Phase III
study in Duchenne Muscular Dystrophy is an important milestone for Santhera's
future. We now anticipate increasing interest from existing and new
investors, licensees as well as the possibility of income from licensing in
the short to mid-term. We further filed the marketing authorization
application for Raxone®in the treatment of Leber's Hereditary Optic
Neuropathy and expect a decision by the European Medicines Agency in the
first half of 2015." Referring to the Santhera's financial situation, he
commented: "Looking ahead, we expect to finance the Company's operations by
income from Raxone®sales, licensing opportunities and appropriate use of
authorized and conditional capital."

* * *

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical
company focused on the development and commercialization of innovative
pharmaceutical products for the treatment of orphan mitochondrial and
neuromuscular diseases.

Santhera recently announced the re-filing of a Marketing Authorization
Application (MAA) for Raxone®in Leber's Hereditary Optic Neuropathy (LHON)
based on additional clinical efficacy data and following pre-filing advice
from EU member states. The compound has been granted orphan drug designation
in the EU and the US. Raxone®would become the first product authorized for
the treatment of this rare, inherited disease which otherwise invariably
leads to blindness. Santhera expects a decision from the European Medicines
Agency in the first half of 2015. Earlier this year, the French National
Agency for the Safety of Medicine and Health Products granted a temporary
authorization for use for Raxone®in LHON patients in France based on a data
package comparable to the submitted MAA dossier.

On May 13, 2014, Santhera announced a positive outcome for its Phase III DELOS
trial in Duchenne Muscular Dystrophy (DMD). The DELOS study randomized 65 DMD
patients who were 10-18 years of age and who were not using concomitant
corticosteroids. The study met the primary endpoint, a statistically
significant difference between Catena®/Raxone®and placebo in the change from
baseline to week 52 in Peak Expiratory Flow. Peak Expiratory Flow is a
measure of respiratory muscle strength, the decline of which is a major
contributing factor to morbidity and mortality in DMD. Catena®/Raxone®(900
mg/day) was safe and well tolerated with adverse event rates comparable to
placebo.

Santhera is collaborating with the National Institutes of Health on a
placebo-controlled Phase II clinical trial for the treatment of primary
progressive Multiple Sclerosis (ppMS), a currently untreatable disease
affecting approximately 60,000 patients in North America and 85,000 in
Europe.

Santhera holds full global patent and/or commercialization rights to all of
its clinical development programs for Catena®/Raxone®. For further
information, please visit the Company's websitewww.santhera.com.

Raxone®and Catena®are trademarks of Santhera Pharmaceuticals.

For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier@santhera.com

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of the Company to be
materially different from those expressed or implied by such statements.
Readers should therefore not place undue reliance on these statements,
particularly not in connection with any contract or investment decision. The
Company disclaims any obligation to update these forward-looking statements.

News release ASM 2014
http://hugin.info/137261/R/1787237/613614.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via Globenewswire

HUG#1787237

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.